Doctors have injected people with the world’s first AI designed vaccine

Researchers at the University of Cambridge have used an Artificial Intelligence (AI) machine learning model to invent a new and wholly novel form of vaccine that could protect against an entire family of human coronaviruses, and even animal variants that are yet to jump over.

An initial human trial has already been completed, the results of which were published in the Journal of Infection, making it the first AI-designed vaccine to be tested in humans. The potential is dazzling: it could future-proof us against deadly virus mutations before they even occur.

“This is about making vaccines that protect us, not just from today’s viruses, but protect us from what can cause the next outbreak or disease,” study coauthor Jonathan Heeney, a Cambridge researcher, told BBC News. “This is a fundamental shift in how we prepare for pandemics.”

The Future of Life Sciences & Healthcare 2040, a keynote by futurist Matthew Griffin

A traditional vaccine trains our immune system to tackle a specific virus. But these vaccines have to be constantly updated as a virus mutates over time, putting doctors on the back foot. That’s why you get new shots every flu season, and why we’re still getting new COVID-19 boosters.

AI-assisted vaccines could be a game changer. Machine learning models can scan virtually the entire corpus of genetic data collected on thousands of related viruses across the world and predict what parts of the virus are most likely to stay the same as the virus evolves, according to an expert’s analysis in The Conversation. If a vaccine focuses on these immutable virus components, it in theory could allow a vaccine to protect against an entire family of viruses - and future mutations of them, too.

And that’s that the researchers did. In the study, the Cambridge scientists focused on the sarbecovirus family, which contains both SARS and COVID, as well as strains of animal coronaviruses. After siccing their AI model on the viruses, it identified the immutable virus components, and from there, the humans narrowed down which ones were the best through careful in vivo experimentation. This allowed them to create a “super-antigen” that formed the key ingredient of the vaccine.

The results of the human trial are promising, but not definitive. It showed that the AI vaccine successfully activated the immune system to produce virus-fighting antibodies. And it was “well tolerated at all four doses with no significant safety concerns elicited,” the researchers reported in the study.

But the trial was small, with just 39 people. The immune response was “modest,” and it’s unclear how long the protection lasts.

The groundwork has been laid though, and the potential payoff would be astonishing: a potential universal vaccine. Even more encouraging is that the developed vaccine is a DNA rather than mRNA based, meaning it doesn’t require needle injections to be administered. It’s also more stable, allowing for easier transport and storage, instead of the tightly controlled, frigid conditions that mRNA vaccines require. It might even help tackle the Ebola crisis in the Democratic Republic Congo, which is being caused by a new strain that doctors don’t have a vaccine for.

“We’ve converted vaccine development from being reactive to being future proof. Our vaccines will continue to provide protection against viruses even as they mutate into new strains,” Heeney said in a statement about the work. “We’ve overcome the problem of traditional vaccines, which have limited protection. It means we can escape the constant cycle of chasing the virus variants circulating in humans and updating the vaccines to try to catch up, like a dog chasing its tail.”

First published on Fanatical Futurist on 17 June 2026.

311 Intelligence

What this means

Analysis by the 311 Strategic Intelligence Unit

The big shift is vaccine development moving from reacting to viruses to designing ahead of them. Cambridge used machine learning to find the parts of a virus family least likely to change, then built a vaccine around them and tested it in people. Our Starburst data shows how far this has to run: we expect DNA Vaccines to reach wide use by 2035, and we rate Predictive Vaccines, with a first product expected in 2034, a Watch technology.

What it means by sector.

• Healthcare and public health: a vaccine that covers future mutations could mean fewer updated shots and boosters. We track Epidemics and Pandemics as an Act now trend that already reached the mainstream in 2020.
• Pharmaceuticals and biotech: AI that scans genetic data from thousands of viruses changes how antigens are chosen. We track AI Accelerated Science as a Prepare trend, with wide use expected by 2030.
• Logistics and global health: a DNA vaccine that is more stable than mRNA is easier to transport and store, which matters in places such as the Democratic Republic of the Congo.

What to do now.

• Treat the early results as promising but not definitive: the trial was small and the immune response modest.
• Review pandemic plans that assume new vaccines must be made after an outbreak starts.
• Track how AI is being used to choose drug and vaccine targets in your own research pipeline.

The Starburst technologies behind this story

From the 311 Technology Starburst (first product, expected wide use and readiness):

Technology	Category	First product	Wide use	Action	TRL
DNA Vaccines	Biotech	2005	2035	Explore	9
Predictive Vaccines	Biotech	2034	2055	Watch	6
Reverse Vaccinology	Biotech	2013	2035	Explore	9
Genome Language Models	Intelligence	2025	2032	Explore	5

And the trends they feed, from the 311 Trends Starburst:

Trend	Wide use	Action
Epidemics and Pandemics	2020	Act now
AI Accelerated Science	2030	Prepare
Pandemic Preparedness Retreat	2027	Act now

How this moves the trend

The groundwork for AI-designed vaccines has been building for years. In 2021 the coronavirus became the first ever virus to be fully digitised. In 2025 MIT developed a vaccine to stop the next Pandemic, and in April 2026 researchers used AI and known genetic codes to create new pandemic vaccines. Cambridge has now taken an AI-designed vaccine into people.

Go deeper with 311

• The 311 Starburst Centre: every technology and trend above, with timelines and readiness.
• 311 Vantage: ask what AI-designed vaccines mean for your organisation and get a plain English executive brief.
• The Exponential Technology Codex and the Annual Trends Codex: the technologies and trends reshaping every industry.
• Book a briefing or keynote on the future of healthcare and life sciences for your board or leadership team.